• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-K filed by Lite Strategy Inc.

    9/26/25 4:00:57 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LITS alert in real time by email

    Unavailable

    Get the next $LITS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LITS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LITS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Lite Strategy Inc.

    SCHEDULE 13G/A - Lite Strategy, Inc. (0001262104) (Subject)

    10/31/25 11:05:28 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Lite Strategy, Inc. (0001262104) (Filer)

    10/30/25 4:00:27 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Lite Strategy Inc.

    S-3 - Lite Strategy, Inc. (0001262104) (Filer)

    10/8/25 4:45:54 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $LITS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations

    SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS") today announced its Board of Directors has authorized a program to repurchase shares of the Company's Common Stock, par value $0.00000002 per share (the "Common Stock"), up to an aggregate amount of $25 million. The share repurchase program is effective immediately, and provides for shares to be repurchased in the open market or through negotiated transactions. "Our top priority is to enhance stockholder value," said Board Member Joshua Riezman, U.S. Chief Strategy Officer at GSR, which is advising the Company on its treasury strategy, "and the share repurchase program is one of th

    10/29/25 9:00:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026

    SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS"), the first U.S.-listed public company to adopt Litecoin as its primary reserve asset, joins the digital asset community in celebrating the 14th anniversary of Litecoin (LTC), and its role as the second-longest-running blockchain in crypto and a model of network resilience. "As we celebrate this historic time, we see that Litecoin's 14-year track record of reliability and uptime continues to attract more institutional interest. As institutions look for digital assets with proven durability and sound hard-money principles, Litecoin stands out as a strong choice for both treasury divers

    10/16/25 4:06:43 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lee Charles Benjamin

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    10/6/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flynn James P was granted 10,000 shares, increasing direct ownership by 127% to 17,900 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    10/2/25 4:00:27 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care